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RadiotherapyAbstract Background: Phyllodes tumors are rare fibroepithelial breast tumors with diverse
biological behavior. Our study aim is to review the clinico-pathological features, prognostic factors
and treatment outcome for patients presenting with phyllodes tumors of the breast to the Kuwait
Cancer Control Center (KCCC).
Patients and methods: We retrospectively reviewed the clinical and pathological data of 35 women
of histologically proved phyllodes tumors of the breast retrieved between January 1994 and Decem-
ber 2012.
Results: The median age was 40 years (21–63 years). The median pathological tumor size was
6.8 cm (3–25 cm). Histologically, one patient (3%) presented with benign, 13 (37%) with borderline
and 21 (60%) with malignant phyllodes. Twenty-eight patients (80%) were premenopausal. Twenty
(57%) were ultimately treated with mastectomy (3 borderline, and 17 malignant) and 15 (43%) with
conservative surgery (1 benign, 10 borderline and 4 malignant). Axillary staging was carried out in 9
patients (1 borderline and 8 malignant), none of them had nodal metastasis. Four patients with
malignant phyllodes received postoperative radiotherapy. After a median follow-up period of
52 months (range 5–211 months), 5 developed local recurrence (1 benign, 2 borderline and 2 malig-
nant). One patient with malignant phyllodes developed distant lung metastasis. The overall 5-year
relapse free survival (RFS) was 74% (68% for borderline and 84% for malignant phyllodes).
According to the treatment modality, the 5-year RFS was 69% for conservative surgery compared
to 87% for mastectomy. It was 100% for irradiated patients versus 71% for non irradiated patients.
Conclusion: Phyllodes tumors are rare tumors that occur in relatively young women, when com-
pared with the classical adenocarcinoma of the breast. They have a tendency to reach large sizes
with absence of nodal metastasis. Although surgery is the mainstay of management, postoperative
radiotherapy also appears to decrease the local recurrence rates in certain presentations.
 2016 National Cancer Institute, Cairo University. Production and hosting by Elsevier B.V. This is an
open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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Phyllodes tumors are rare fibroepithelial breast tumors that
account for fewer than 0.5% of all breast malignancies [1,2].
They are characterized by a diverse range of biologic behavior.
The least aggressive form may behave similar to fibroadeno-
mas, yet with a high local recurrence rate if excised without
wide margins, while its malignant form can give distant metas-
tasis [3,4].
Phyllodes tumors are classified as benign, borderline or
malignant [1,3,5] according to the degree of stromal cellular
atypia, mitotic activity, infiltrative versus circumscribed
tumor margins and presence or absence of stromal over-
growth [6–9]. The stromal elements are key components in
the differentiation of phyllodes tumors from fibroadenomas
and in distinguishing a benign from a malignant phyllodes
tumor [7].
The main treatment of phyllodes tumors remains surgical
excision. Wide local excision, with a margin of at least 1 cm
is the most effective surgery [1,4,10] for nonmalignant as well
as malignant lesions. Re-excision is indicated when necessary
to ensure adequate margins as the recurrence rates are unac-
ceptably high following excision with inadequate margins
[11–17]. The local recurrence rates following wide local exci-
sion are 8% for benign phyllodes tumors and 21–36% for bor-
derline and malignant tumors [10,12].
Adjuvant radiotherapy (RT) for phyllodes tumors is con-
troversial. Radiotherapy is unnecessary for benign phyllodes
tumors that are widely excised. However, adjuvant RT
appears to be effective in decreasing recurrences after breast
conserving resection for borderline or malignant phyllodes
tumors [10,14,17] particularly when it is not possible to
obtain a wide margin of P1 cm of resection. For some
tumors a 1 cm margin may not be possible even with a
total mastectomy due to their size or location. Available
data indicate that RT will substantially reduce recurrence
for these patients [10]. There is less agreement about the
role of adjuvant RT when wide margins P1 cm can be
obtained.
The benefit of adjuvant chemotherapy is controversial. It
should be administered only for a minority of patients with
large, high-risk or recurrent malignant tumors, and only after
a thorough discussion about the risks and benefits of treat-
ment. Hormone therapy is not effective for phyllodes tumors
despite the presence of positive hormone receptors in the
epithelial component of some of these tumors [18,19].
The majority of patients with benign and borderline phyl-
lodes tumors are cured with surgery. The survival rate for
malignant phyllodes tumors is reported as approximately 60–
80% at 5 years [4,11,20]. Metastatic disease has been reported
in 13–40% of patients [1,3,4]. Metastases most frequently
involve the lungs. After the development of metastases, mean
overall survival is 30 months [21].
Aim of the study
This is a retrospective study that aims at revision of the clinico-
pathological features, prognostic factors and treatment out-
come for patients who presented with phyllodes tumors of
the breast to the Kuwait Cancer Control Center (KCCC).Patients and methods
The medical index of the KCCC is a computerized record of all
the diagnoses made or revised at the KCCC. The KCCC is the
only multidisciplinary cancer center in the State of Kuwait to
which all patients are referred from different provinces of
Kuwait. A search of the index from January 1994 to December
2012, using the term phyllodes tumors, revealed 35 cases.
The clinical and pathological data were retrospectively
studied from the medical and pathologic records. Disease free
survival was estimated using Kaplan Meier method. DFS was
defined as the time from diagnosis to the date of first recur-
rence. Patients without documented recurrent disease were
censored at the last date of their follow up. Statistical signifi-
cance was calculated by using the log-rank test and defined
as P< 0.05.
Results
The characteristics of the 35 patients are summarized in
Table 1. All patients were females with a median age at diag-
nosis of 40 years (range 21–63). The median follow-up was
52 months (range 5–211 months). Twenty-eight (80%) were
premenopausal. No patients reported family history of breast
cancer. All patients presented with a breast mass, four with
tumor ulceration. Mammography was employed in 11
patients, 5 were reported as BIRADS 3, 4 as BIRADS 4 and
2 as BIRADS 5. One patient presented with benign phyllodes,
thirteen had borderline phyllodes (37%) and 21 had malignant
phyllodes (60%). Initially 18 were subjected to conservative
surgery however 7 showed inadequate surgical margin.
Secondary surgery was wider excision in 4 and mastectomy
in 3. Overall mastectomy was the definitive surgery in 20
(57%). Surgical axillary staging was performed in 9 patients
(axillary sampling in 5 patients and formal dissection in 4
patients), all of them showed no nodal metastasis. The most
frequent tumor site was the upper outer quadrant reported
in 17 patients (48.5%) while the second frequent was the
involvement of the whole breast in 11 patients (31.5%). The
median pathologic tumor size was 6.8 cm (range 3–25 cm),
however for ulcerative tumors it was 18 cm (range 12–25).
Adjuvant RT was employed in 4 patients (following mastec-
tomy in 3 patients and conservative surgery in one). The four
patients presented with large malignant phyllodes tumors
(median size of 16 cm). The dose of postmastectomy RT was
50 Gy/25 fractions in two and 60 Gy/30 fractions in the third.
Following conservative surgery, the RT dose was 50 Gy/25
fractions + 14 Gy/7 fractions as a tumor bed boost. None of
the 4 patients experienced local recurrence.
Local recurrence was experienced in 5 patients (one benign,
2 borderline and 2 malignant phyllodes). Histopathology of
recurrence was similar to the original pathology in all cases.
Two patients were treated with wide local excision and 3 with
mastectomy. One patient treated for malignant phyllodes
developed distant lung metastasis and lost follow-up. One
patient who was treated for malignant phyllodes with wide
excision and RT developed ipsilateral DCIS after 10 years
and was managed with mastectomy (see Figs. 1–4).
The relapse group had a median age of 37 years
(25–63 years) and a median tumor size of 5 cm (3–16 cm).
Table 1 Patients and tumor characteristics of 35 cases of phyllodes tumors of the breast presented to KCCC from 1994 to 2012.
All cases Borderline phyllodes Malignant phyllodes
Age
Median 40 years 40 years 39 years
Range 21–63 years 30–63 years 21–53 years
Diﬀerentiation
Benign 1 (3%) NA NA
Borderline 13 (37%) NA NA
Malignant 21 (60%) NA NA
Menopausal status
Premenopausal 28 (80%) 10 17
Postmenopausal 7 (20%) 3 4
Clinical tumor size
Median 5.7 cm 4 cm 7.5 cm
Range 3–20 cm 3–14 cm 3–20 cm
Site of the tumor
UOQ 17 (48.6%) 7 (53.8%) 9 (42.9%)
LOQ 3 (8.6%) 2 (15.4%) 1 (4.8%)
UIQ 2 (5.7%) 1 (7.7%) 1 (4.8%)
LIQ 1 (2.9%) 1 (7.7%) 0
Retroareolar 1 (2.9%) 1 (7.7%) 0
More than 1 quadrant 11 (31.3%) 1 (7.7%) 10 (47.6%)
Initial surgery
Mastectomy 17 (48.5%) 3 (23%) 14 (66.7%)
Conservative surgery 18 (51.5%) 10 (77%) 7 (33.3%)
Pathologic size
Median 6.8 cm 4.5 cm 11.5 cm
Range 3–25 cm 3–20 cm 3.5–25 cm
Surgical margin
Negative 28 (80%) 11 (85%) 16 (76%)
Positive 7 (20%) 2 (15%) 5 (24%)
Overall surgery
Mastectomy 20 (57%) 3 (23%) 17 (81%)
Conservative surgery 15 (43%) 10 (77%) 4 (19%)
Axillary staging
Yes 9 (26%) 1 (7.7%) 8 (38%)
No 26 (74%) 12 (92.3) 13 (62%)
Radiation therapy
Yes 4 (11.5%) 0 4 (19%)
No 31 (88.5%) 13 (100%) 17 (81%)
Recurrence
Yes 5 (14%)* 2 (15.5%) 2 (9.5%)
No 29 (86%) 11 (84.5%) 19 (89.5%)
Surgery of recurrence
Wide excision 2 (40%) 2 (100%) 0
Mastectomy 3 (60%) 0 3 (100%)
Distant metastasis
Yes 1 (3%) 0 1 (5%)
No 34 (97%) 13 (100%) 20 (95%)
Follow-up
Median 52 months 52.5 months 45 months
Range 5–211 months 12–154 months 5–211 months
* One patient treated for benign phyllodes had local recurrence.
Phyllodes tumors of the breast 245The 5-year relapse free survival (RFS) was 74 ± 10%. It
was 68 ± 20% for borderline and 84 ± 8% for malignant
phyllodes (P= 0.9). The four patients who received adjuvant
RT did not develop relapse (5-years RFS 71 ± 11% for nonirradiated versus 100% for irradiated patients, P= 0.3).
According to the type of surgery the 5-year RFS was 69
± 14% for WLE versus 87 ± 9% for mastectomy patients
(P= 0.4).
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Figure 1 Relapse free survival curve for the 35 patients
presented with phyllodes tumor of the breast.
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Figure 2 Relapse free survival curve for patients presented with
malignant and borderline phyllodes tumors of the breast.
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Figure 3 Relapse free survival curve for patients treated with
and without adjuvant radiotherapy for phyllodes tumors of the
breast.
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Figure 4 Relapse free survival curve for patients treated mas-
tectomy versus conservative surgery for phyllodes tumors of the
breast.
246 G.A. Demian et al.Discussion
Phyllodes tumors are rare tumors with an average annual inci-
dence rate of 2.1 per million women [6]. We retrieved 35 female
patients diagnosed in KCCC in a 19 year period. Phyllodes
tumors of the breast present in a younger age population com-
pared to adenocarcinoma. The median age is 40 years com-
pared to 52 years for breast adenocarcinoma in Kuwait [22]
and comparable to the reported 42–45 years worldwide
[6,23,25].
Phyllodes tumors are generally first identified as a breast
mass or an abnormal mammographic finding. The median
tumor size in our study is 5.7 cm, larger for malignant phyl-
lodes (7.5 cm) compared to the borderline subtype (4 cm) likely
due to more rapid growth pattern. Larger tumors ulcerated by
pressure necrosis to the skin. The reported median size in theliterature is 4–7 cm [1,23]. However, for borderline and malig-
nant phyllodes, Mallick et al. reported a median size of
13.6 cm [24].
The typical appearance of a phyllodes tumor on mammog-
raphy is a smooth, polylobulated mass resembling a fibroade-
noma explaining why five out of the eleven mammographies
done reported a probably benign mass (BIRADS 3). Gener-
ally, mammography was underused in our patients as many
patients were managed in general hospitals and in the early
1990s. Also, many patients presented with locally advanced
disease making the mammographic assessment of no value.
Suspicion for a phyllodes tumor rather than a fibroadenoma
is based on large tumor size at presentation or rapid growth
[3]. Image guided core biopsy is now our standard of care
before surgical management of any breast mass.
Phyllodes tumors of the breast 247Only one patient presented with benign phyllodes in our
series while in many series, benign phyllodes represented
50% of phyllodes tumors [3,8]. This may be explained by the
reluctance of surgeons operating on benign phyllodes to refer
patients to a cancer center. In our study, the probability of
having a positive surgical margin after conservative surgery
is higher with malignant phyllodes compared to borderline
(24% vs. 15%) likely due to the infiltrative nature of the
tumor. The overall mastectomy rate for the malignant phyl-
lodes was 81% compared to 23% for the borderline secondary
to larger tumor size and higher positive margin rate.
Despite axillary node metastases being rare (only eight of
498 women in the SEER database) [11], nine patients had axil-
lary surgical staging (sentinel lymph node biopsy in 3, axillary
sampling in 2 and axillary dissection in 4) mostly for malignant
phyllodes. None of them had nodal metastasis. Axillary dissec-
tion is not recommended, however many patients were referred
to our center following surgery.
Adjuvant radiotherapy lowered the rates of local recurrence
in malignant and borderline tumors [17]. Radiotherapy was
underused in our study. It was employed in only 4 patients
with large malignant tumors, none of them experienced local
relapse.
The local recurrence rate was 14% comparable with the
recurrence rates reported in the literature (8–19%). In some
reports, it reached to 36% [17]. Only one patient developed
distant metastasis in our study, the reported rates of distant
metastasis ranged from 2.4% to 7.5% [1,14,26,27]. The num-
ber of patients who relapsed was relatively small. The tumor,
patients and treatment characteristics were not significantly
different between the relapsed and non relapsed groups.
The follow-up of our patients who were treated for phyl-
lodes tumors follows the same breast cancer follow-up proto-
col as defined by NCCN guidelines [28]. However, a report
from UK advices against routine follow up of these cases [29].
Conclusion
Phyllodes tumors are rare tumors that occur in relatively young
women, when compared with the classical adenocarcinoma of
the breast. They have a tendency to reach large sizes with
absence of nodal metastasis. Although surgery is the mainstay
of management, postoperative radiotherapy also appears to
decrease the local recurrence rates in certain presentations.
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